8:00 am Registration & Morning Coffee

8:45 am Chair’s Opening Remarks

• Mokkram Hossain Senior Scientist, AstraZeneca

Current Cutting-Edge Advancements in Progress to Innovate Myeloid Cell Therapies for Enhanced Therapeutic Outcomes

9:00 am Targeting Multiple Immune Cell Types to Promote Maximum Efficacy

• Charlene Liao President & chief executive officer, Immune-Onc Therapeutics Inc.

9:30 am Reprogramming Myeloid Cells for Enhanced Target Selection & Improved Therapy Efficacy

• Aditya Murthy Director, Immuno-oncology, Gilead Sciences

10:00 am Exploring the Benefits of Myeloid Spatial Biology for Enhanced Insight into TME Interactions with Myeloid Cells

• Miriam Merad Professor & Director - Medicine, Precision Immunology Institute, Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai

10:30 am Morning Refreshments & Speed Networking

Harnessing the Untapped Potential of Neutrophils for Unparalleled Benefits in Targeted Treatment

11:30 am Retinoic Acid Receptor Related Orphan Receptor Gamma (RORg) & RORgt & Its Role in Being a Cancer-Specific Novel Target

• Jean Tchervenkov Professor, McGill University
• Jonathan Cools Lartigue Associate Professor, McGill University

12:30 pm Lunch & Networking

Decoding the Impact of Tumor Microenvironment on Myeloid Cells for Enhanced Clinical Insight

1:30 pm Round Table Discussion: Improving the Translatability of Myeloid-Targeted Therapies in Preclinical Models

• Stephanie Casey Parks Principal Scientist, Amgen Inc.

2:15 pm Unbiased Discovery of Novel Myeloid-Directed Therapies for Cancer

• Kipp Weiskopf Co-founder/Fellow, DEM Biopharma

2:45 pm Afternoon Refreshments & Poster Session

3:15 pm ACTM-838: A Novel Microbial Modality That Safely Enriches in TME After IV Dosing & Comprehensively Reactivates the Immunosuppressive TME for a Durable Anti-Tumor Immunity

• AKSHATA UDYAVAR Senior Director - Immunology & Translational Sciences, Actym Therapeutics Inc.

3:45 pm Panel Discussion – Understanding the Benchmarks of Progression When Moving Into the Clinic

• Aditya Murthy Director, Immuno-oncology, Gilead Sciences
• Miriam Merad Professor & Director - Medicine, Precision Immunology Institute, Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai
• Barbara Platzer Associate Director, Novartis AG
• Jashodeep Datta Assistant Professor - Surgery, University of Miami

4:30 pm Chair’s Closing Remarks